US Patent
US7803839 — Azetidines as MEK inhibitors for the treatment of proliferative diseases
Composition of Matter · Assigned to Exelixis Inc · Expires 2029-11-10 · 3y remaining
Vulnerability score
10/100
Ironclad — strong claim type, well-established, deep family
What this patent protects
This patent protects compounds of Formula (I) and their pharmaceutically acceptable salts and solvates, which are MEK inhibitors for treating proliferative diseases like cancer.
USPTO Abstract
Disclosed are compounds of Formula (I) and pharmaceutically acceptable salts and solvates thereof. Such compounds are MEK inhibitors and are useful in the treatment of proliferative diseases, such as cancer. Also disclosed are pharmaceutical compositions containing such compounds as well as methods of using the compounds and compositions of the invention in the treatment of cancer.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.